All In Biotech

Drug Trial Radar · NCT06154343

A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

A Phase 1, First-In-Human, Multicenter, Open-Label,Dose-Escalation and Extension Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

150

Planned (sponsor's estimate)

Start

Nov 23, 2022

Primary completion

Dec 31, 2024

Study completion Jul 30, 2025

Sponsor

Sponsor type
Industry
First posted
Dec 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of GQ1005 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.

Conditions

  • HER2 Expressing or Mutated Advanced Malignant Solid Tumors

Interventions

  • GQ1005Drug

    an antibody drug conjugate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Adverse Events (AEs)Time frame: Up to 2 years
  2. Dose Limiting Toxicities (DLTs)Time frame: From first dose to the end of Cycle 1, 21 days
  3. Maximal Tolerance Dose (MTD) or recommended phase II dose (RP2D)Time frame: After each cohort completes the DLT observation period (Day 1 to Day 21 after the first dose of study treatment) or has a DLT or becomes not DLT-evaluable

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA general hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • The First Affiliated Hospital of Haerbin Medical University

    Haerbin, Heilongjiang, China · Recruiting

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Affiliated Drum Tower Hospital, Medical School of Nanjing University

    Nanjing, Jiangsu, China · Recruiting

  • Shengjing hospital of China medical universty

    Shenyang, Liaoning, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Recruiting

  • Linyi Cancer Hospital

    Linyi, Shandong, China · Recruiting

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, China · Recruiting

  • Fudan university Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • The First Affiliated Hospital of Xi'an University

    Xi'an, Shangxi, China · Recruiting

  • Suining Central Hospital

    Suining, Sichuan, China · Recruiting

  • Sichuan Cancer Hospital

    Chengdu, Sichuang, China · Recruiting

  • Tianjin medical university cancer institute & hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.